This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Switchover study from Botox to Xeomin for facial dystonia

Switchover study from Botox to Xeomin for facial dystonia
Reviewed by Ivan Yip

7 April 2021 | Ivan Yip | EYE - Neuro-ophthalmology | facial dystonia, incobotulinumtoxinA, onabotulinumtoxinA
Share This

This study carried out in the UK compared the clinical effectiveness and efficiency of switching patients from Botox® injections to Xeomin®. This was carried out in 20 essential blepharospasm, 12 hemifacial spasm and six aberrant facial nerve regeneration patients. Patients were masked and had three Botox® injections compared to three subsequent Xeomin® injections of the same unit dose. Xeomin® was equivalent to Botox® in effectiveness and statistically subjectively better in hemifacial spasm. Patients felt the duration of maximal effect was one week longer for Xeomin®. Side-effect profile was also similar. Xeomin® is 33% cheaper per unit and does not require refrigeration. This was an interesting study as it directly compared these patients with a number of injections over several years. From personal experience at several different NHS trusts where botulinum toxin can vary between clinics, this article provides evidence to obtain a consistent supply of one brand.

Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.
Bladen J, Favor M, Litwin A, Malhotra R.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
2020;48:1146-51.
Share This
CONTRIBUTOR
Ivan Yip

Alder Hey Children's Hospital, Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency